Sempre Health launched Atlas on 16 November 2026, an artificial intelligence voice service sold to pharmaceutical manufacturers, health plans and pharmacy benefit managers. The San Francisco company says Atlas takes the telephone work that sits between a prescription and a patient starting treatment, and that it ran the technology on its own patient support programme before selling it to anyone else.1
Atlas is pitched at two buyers. For manufacturers it covers hub services: calling payers about benefits, prior authorisation and appeals, chasing provider offices for missing information, and reaching patients about enrolment, shipping and adherence. For health plans and pharmacy benefit managers it answers member services calls on enrolment, affordability and refills at any hour, under the plan's own brand, and Sempre says it speaks only from plan-approved content. When a caller needs a person, the service hands the call over with its context attached.1
What Sempre says it has built
The figures Sempre gives are about its own operations rather than customer results. The company began automating pharmacy calls in 2018 and was granted a patent in 2020 for technology that works through pharmacy phone trees. By 2024 its agents were holding full conversations with pharmacy staff, and it says AI now places every outbound pharmacy call the company makes. On pharmacy calls alone its agents have spent more than 22,000 hours on the telephone for more than 70,000 patients, and the underlying technology was built across more than 1.3 million support calls. Sempre holds contracts and business associate agreements with 19 health plans and pharmacy benefit managers through its affordability business, which it says gives Atlas a direct route to payers.1
The commercial model is the part worth noting. Most voice AI is sold as software the customer configures and runs. Sempre says it operates Atlas on the customer's behalf and takes responsibility for the outcome, with its own staff auditing calls and tuning the agents. "Our customers don't want another AI tool to manage," said Anurati Mathur, chief executive and co-founder of Sempre Health. "They want patients to get answers and get on therapy faster."1
What it means for the market
Patient access is where a launch now gets judged commercially, not where a molecule is designed. If a manufacturer can buy a managed service that is accountable for time to therapy rather than a licence for call software, the comparison shifts from feature lists to performance, and from the IT budget to the brand team's. That favours vendors that can carry delivery risk and already hold payer agreements, and it puts pressure on voice AI suppliers selling a self-managed platform into the same hubs.1
Two details matter for regulatory and safety teams. Sempre says every Atlas call is recorded, transcribed and reviewed, and that it captures and reports adverse events and product quality complaints, which places an automated channel inside a manufacturer's pharmacovigilance obligations. It also says Atlas goes live on existing telephone lines without a system integration, and that the company holds HITRUST r2 certification including the HITRUST AI security assessment.1
The claims come from Sempre alone. The announcement gives no customer named as using Atlas, no pricing, and no measured effect on time to therapy, call resolution or adherence for any manufacturer or plan; the operating figures describe Sempre's own programme, not a buyer's results. Hub services and member services calls are the first use cases on offer, and Sempre says it plans to add more.1
Sources
- Sempre Health Launches Atlas, an AI Voice Service for Life Science Hubs, Payers, and PBMs (opens in a new tab)PR Newswire · prnewswire.com
This briefing summarises publicly available research and reporting for information only. It is not medical, investment or legal advice. Follow the sources listed for the primary research and reporting.